1
Clinical Trials associated with SLAMF7 FPBMC(University of Virginia)Phase I/II Study of Anti-CD3 x Anti-SLAMF7 (Anti-CS-1) Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells (SLAMF7 FPBMC) in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-SLAMF7 bispecific antibody fresh peripheral blood mononuclear cells (SLAMF7 FPBMC/CS1 FPBMC) for patients with relapsed and/or refractory multiple myeloma. Patients receive 8 weekly doses and then 8 more doses every 2 weeks of SLAMF7 FPBMC by intravenous infusion.
100 Clinical Results associated with SLAMF7 FPBMC(University of Virginia)
100 Translational Medicine associated with SLAMF7 FPBMC(University of Virginia)
100 Patents (Medical) associated with SLAMF7 FPBMC(University of Virginia)
100 Deals associated with SLAMF7 FPBMC(University of Virginia)